These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 16614227)

  • 21. Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab era.
    Palmieri C; Shah D; Krell J; Gojis O; Hogben K; Riddle P; Ahmad R; Tat T; Fox K; Porter A; Mahmoud S; Kirschke S; Shousha S; Gudi M; Coombes RC; Leonard R; Cleator S
    Clin Breast Cancer; 2011 Apr; 11(2):93-102. PubMed ID: 21569995
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.
    Bendell JC; Domchek SM; Burstein HJ; Harris L; Younger J; Kuter I; Bunnell C; Rue M; Gelman R; Winer E
    Cancer; 2003 Jun; 97(12):2972-7. PubMed ID: 12784331
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
    Lipton A; Köstler WJ; Leitzel K; Ali SM; Sperinde J; Weidler J; Paquet A; Sherwood T; Huang W; Bates M;
    Cancer; 2010 Nov; 116(22):5168-78. PubMed ID: 20661914
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer.
    García-Sáenz JA; Martín M; Puente J; López-Tarruella S; Casado A; Moreno F; Grande E; Díaz-Rubio E
    Clin Breast Cancer; 2005 Oct; 6(4):325-9. PubMed ID: 16277882
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A retrospective analysis of trastuzumab-based therapy in metastatic breast cancer patients at Masaryk Memorial Cancer Institute. Identification of predictive factors].
    Svoboda M; Grell P; Simícková M; Fabian P; Petráková K; Palácová M; Macková D; Trojanec R; Hajdúch M; Pavlík T; Nenutil R; Vyzula R
    Klin Onkol; 2008; 21(6):348-58. PubMed ID: 19382598
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers.
    Marcom PK; Isaacs C; Harris L; Wong ZW; Kommarreddy A; Novielli N; Mann G; Tao Y; Ellis MJ
    Breast Cancer Res Treat; 2007 Mar; 102(1):43-9. PubMed ID: 16897431
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trastuzumab treatment in multiple lines: current data and future directions.
    Pegram M; Liao J
    Clin Breast Cancer; 2012 Feb; 12(1):10-8. PubMed ID: 22154153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 4-years results of weekly trastuzumab and paclitaxel in the treatment of women with HER2/neu overexpressing advanced breast cancer: single institution prospective study.
    Janku F; Pribylova O; Zimovjanova M; Pazdrova G; Safanda M; Zemanova M; Petruzelka L
    Bull Cancer; 2004 Oct; 91(10):E279-83. PubMed ID: 15582895
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
    Dank M
    Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab.
    Montagna E; Cancello G; D'Agostino D; Lauria R; Forestieri V; Esposito A; Silvestro L; Accurso A; De Placido S; De Laurentiis M
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):275-80. PubMed ID: 18379783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Central nervous system metastases in breast cancer patients administered trastuzumab.
    Duchnowska R; Szczylik C
    Cancer Treat Rev; 2005 Jun; 31(4):312-8. PubMed ID: 15979804
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer.
    Chang HR
    Cancer; 2010 Jun; 116(12):2856-67. PubMed ID: 20564392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantitation of HER2 expression or HER2:HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISH.
    Desmedt C; Sperinde J; Piette F; Huang W; Jin X; Tan Y; Durbecq V; Larsimont D; Giuliani R; Chappey C; Buyse M; Winslow J; Piccart M; Sotiriou C; Petropoulos C; Bates M
    Diagn Mol Pathol; 2009 Mar; 18(1):22-9. PubMed ID: 19214112
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implementation of trastuzumab in conjunction with adjuvant chemotherapy in the treatment of non-metastatic breast cancer in the Netherlands.
    de Munck L; Schaapveld M; Siesling S; Wesseling J; Voogd AC; Tjan-Heijnen VC; Otter R; Willemse PH
    Breast Cancer Res Treat; 2011 Aug; 129(1):229-33. PubMed ID: 21431871
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Results from an observational trial with oral vinorelbine and trastuzumab in advanced breast cancer.
    Bartsch R; Wenzel C; Altorjai G; Pluschnig U; Bachleitner-Hoffmann T; Locker GJ; Rudas M; Mader R; Zielinski CC; Steger GG
    Breast Cancer Res Treat; 2007 May; 102(3):375-81. PubMed ID: 17028979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extended survival in women with brain metastases from HER2 overexpressing breast cancer.
    Church DN; Modgil R; Guglani S; Bahl A; Hopkins K; Braybrooke JP; Blair P; Price CG
    Am J Clin Oncol; 2008 Jun; 31(3):250-4. PubMed ID: 18525303
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rational use of trastuzumab in metastatic and locally advanced breast cancer: implications of recent research.
    Goel S; Chirgwin J; Francis P; Stuart-Harris R; Dewar J; Mileshkin L; Snyder R; Michael M; Koczwara B
    Breast; 2011 Apr; 20(2):101-10. PubMed ID: 21183347
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study.
    Campiglio M; Bufalino R; Sandri M; Ferri E; Aiello RA; De Matteis A; Mottolese M; De Placido S; Querzoli P; Jirillo A; Bottini A; Fantini M; Bonetti A; Pedani F; Mauri M; Molino A; Ferro A; Pupa SM; Sasso M; Ménard S; Balsari A; Tagliabue E
    Breast Cancer Res Treat; 2011 Jul; 128(1):147-54. PubMed ID: 21479926
    [TBL] [Abstract][Full Text] [Related]  

  • 39. European oncologists' preferences for the management of breast cancer: case presentations and expert commentary.
    Anderssona M; Awadab A; Barrett-Leec P; Ellisd P; Hupperetse P; Jackischf C; Kubistag E; Lückh HJ; Monnerati C; Nitzj U; Untchl M
    Breast; 2008 Feb; 17 Suppl 2():S1-S12. PubMed ID: 18439963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness analysis of trastuzumab (herceptin) in HER2-overexpressed metastatic breast cancer.
    Perez-Ellis C; Goncalves A; Jacquemier J; Marty M; Girre V; Roché H; Brain E; Moatti JP; Viens P; Le Corroller-Soriano AG
    Am J Clin Oncol; 2009 Oct; 32(5):492-8. PubMed ID: 19487912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.